skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Nuclear medicine in oncology

Journal Article · · Transactions of the American Nuclear Society
OSTI ID:426291

Radioactivity was discovered in the late 1890s, and as early as 1903, Alexander Graham Bell advocated that radioactivity be used to treat tumors. In 1913, the first paper describing therapeutic uses of radium was published; in 1936, {sup 24}Na was administered as a therapy to a leukemia patient. Three years later, uptake of {sup 89}Sr was noted in bone metastases. During the 1940s, there was increasing use of iodine therapy for thyroid diseases, including thyroid cancer. Diagnostic {open_quotes}imaging{close_quotes} with radioisotopes was increasingly employed in the 1930s and 40s using probes and grew in importance and utility with the development of scintillation detectors with photorecording systems. Although coincidence counting to detect positron emissions was developed in 1953, the first medical center cyclotron was not installed until 1961. The 1960s saw the development of {sup 99m}Tc-labeled radiopharmaceuticals, emission reconstruction tomography [giving rise to single photon emission computed tomography (SPECT) and positron emission tomography (PET)], and {sup 64}Ga tumor imaging. Nuclear medicine was recognized as a medical specialty in 1971. Radiolabeled antibodies targeting human tumors in animals was reported in 1973; antibody tumor imaging in humans was reported in 1978. Technology has continued to advance, including the development of SPECT cameras with coincidence detection able to perform FDG/PET imaging. With this overview as as backdrop, this paper focuses on the role of nuclear medicine in oncology from three perspectives: nonspecific tumor imaging agents, specific tumor imaging agents, and radioisotopes for tumor therapy. In summary, while tumor diagnosis and treatment were among the first uses explored for radioactivity, these areas have yet to reach their full potential. Development of new radioisotopes and new radiopharmaceuticals, coupled with improvements in technology, make nuclear oncology an area of growth for nuclear medicine.

OSTI ID:
426291
Report Number(s):
CONF-961103-; ISSN 0003-018X; TRN: 96:006307-0010
Journal Information:
Transactions of the American Nuclear Society, Vol. 75; Conference: Winter meeting of the American Nuclear Society (ANS) and the European Nuclear Society (ENS), Washington, DC (United States), 10-14 Nov 1996; Other Information: PBD: 1996
Country of Publication:
United States
Language:
English

Similar Records

Monte Carlo methods for the simulation of positron emitters in SPECT systems
Journal Article · Tue Dec 31 00:00:00 EST 1996 · Transactions of the American Nuclear Society · OSTI ID:426291

Imaging in Diagnostic Nuclear Medicine
Journal Article · Sat Sep 15 00:00:00 EDT 2018 · Technical Physics · OSTI ID:426291

PRODUCTION CONSIDERATIONS FOR THE CLASSICAL PET NUCLIDES.
Book · Mon Jun 25 00:00:00 EDT 2001 · OSTI ID:426291